147 related articles for article (PubMed ID: 22359284)
1. Epigenetic markers of early tumor development.
Dumitrescu RG
Methods Mol Biol; 2012; 863():3-14. PubMed ID: 22359284
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
3. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer.
Lee BB; Lee EJ; Jung EH; Chun HK; Chang DK; Song SY; Park J; Kim DH
Clin Cancer Res; 2009 Oct; 15(19):6185-91. PubMed ID: 19773381
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
7. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic targets in cancer epidemiology.
Dumitrescu RG
Methods Mol Biol; 2009; 471():457-67. PubMed ID: 19109794
[TBL] [Abstract][Full Text] [Related]
9. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
12. The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer.
Pirouzpanah S; Taleban FA; Atri M; Abadi AR; Mehdipour P
Cancer Causes Control; 2010 Dec; 21(12):2101-11. PubMed ID: 20711807
[TBL] [Abstract][Full Text] [Related]
13. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2009 Oct; 104(7):896-901. PubMed ID: 19522860
[TBL] [Abstract][Full Text] [Related]
14. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
16. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
17. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung.
Licchesi JD; Westra WH; Hooker CM; Herman JG
Clin Cancer Res; 2008 May; 14(9):2570-8. PubMed ID: 18451218
[TBL] [Abstract][Full Text] [Related]
19. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
[TBL] [Abstract][Full Text] [Related]
20. A gene hypermethylation profile of human cancer.
Esteller M; Corn PG; Baylin SB; Herman JG
Cancer Res; 2001 Apr; 61(8):3225-9. PubMed ID: 11309270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]